Camptothecin improves sorafenib sensitivity by inhibiting Nrf2‑ARE pathway in hepatocellular carcinoma

Sorafenib is a targeted drug for hepatocellular carcinoma (HCC), however, its efficacy is limited. Nuclear factor erythroid 2-related factor 2 (Nrf2) contributes to sorafenib resistance. The present study investigated camptothecin (CPT) as a Nrf2 inhibitor to sensitize HCC to sorafenib. The effect o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Liwei, Wang, Hankang, Liu, Qian, Meng, Fanguang, Zhang, Jinliang, Li, Xiaodong, Chang, Shulin, Li, Guijie, Chen, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926516/
https://www.ncbi.nlm.nih.gov/pubmed/36734286
http://dx.doi.org/10.3892/or.2023.8492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926516/
https://www.ncbi.nlm.nih.gov/pubmed/36734286
http://dx.doi.org/10.3892/or.2023.8492

Ejemplares similares